8-K Announcements
6Material company update
Mar 21, 2023·SEC
Material company update
Jan 31, 2023·SEC
Material company update
Nov 14, 2022·SEC
CASI Pharmaceuticals, Inc.(CASI)Earnings, Financials & Key Ratios
CASI•NASDAQ
$0.15
Price updated Jun 20, 2026
AboutCASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.Show more
- Revenue$29M-15.8%
- EBITDA-$37M-74.8%
- Net Income-$39M-45.7%
- EPS (Diluted)-2.56-26.7%
- Gross Margin39.06%-34.0%
- EBITDA Margin-130.67%-107.5%
- Operating Margin-138.84%-87.6%
- Net Margin-137.57%-73.0%
- ROE-301.8%-410.3%
CASI Price & Volume
CASI Pharmaceuticals, Inc. (CASI) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operating Losses Threaten Corporate Solvency
Investment Thesis • Updated 2025Q3
VerdictNeutral
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and solvency
Key Thesis Takeaways
- CASI Pharmaceuticals faces a critical inflection point as its commercial model struggles to gain traction in the Chinese oncology market, evidenced by a 60.5% year-over-year revenue decline in 2025Q3.
- The company's reliance on in-licensed assets has failed to generate positive free cash flow, leading to a precarious liquidity position characterized by a current ratio of 0.30.
- Investors should monitor the firm's ability to address its negative equity of $28.6 million, as the current trajectory suggests significant risk of further capital dilution or operational insolvency.
Verdict Logic
Negative: The company's current ratio of 0.30 and persistent operating losses of $10.7 million in 2025Q3 indicate severe liquidity constraints that outweigh potential upside.
CASI Growth Metrics
CASI Pharmaceuticals, Inc. (CASI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years103.24%
5 Years47.19%
3 Years-1.84%
TTM21.72%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-59.58%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-41.7%
Return on Capital
10 Years-20.22%
5 Years-50.01%
3 Years-55.64%
Last Year-104.59%
Peers Comparison
Key metrics vs top competitors for CASI Pharmaceuticals, Inc. (CASI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.15 | $2.33M | -0.06 | -15.77% | -137.57% | -301.8% | 31.1% | |
| $19.08 | $2.11B | -11.93 | 15.33% | -39.29% | -24.32% | — | |
| $28.04 | $5.19B | -17.53 | 64.04% | -21.97% | -24.91% | — | |
| $25.33 | $1.86B | -23.45 | 38.87% | -126.33% | -0.25% | — | |
| $0.29 | $184M | -0.64 | 96.69% | -39.68% | -60.72% | — | |
| $80.78 | $9.58B | 31.55 | 37.55% | 23.13% | 126.27% | — |
Compare CASI vs Peers
CASI Pharmaceuticals, Inc. (CASI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CASI SEC Filings & Documents
CASI Pharmaceuticals, Inc. (CASI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CASI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CASI Frequently Asked Questions
CASI Pharmaceuticals, Inc. (CASI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is CASI Pharmaceuticals, Inc.'s revenue?
CASI Pharmaceuticals, Inc. (CASI) reported $26.8M in revenue for fiscal year 2024. This represents a 3629% increase from $0.7M in 1995.
How fast is CASI Pharmaceuticals, Inc. growing?
CASI Pharmaceuticals, Inc. (CASI) saw revenue decline by 15.8% over the past year.
Is CASI profitable?
CASI Pharmaceuticals, Inc. (CASI) reported a net loss of $49.4M for fiscal year 2024.
Dividend & Returns
Does CASI pay dividends?
Yes, CASI Pharmaceuticals, Inc. (CASI) pays a dividend with a yield of 31.10%. This makes it attractive for income-focused investors.
What is CASI's return on equity?
CASI Pharmaceuticals, Inc. (CASI) has a return on equity (ROE) of -301.8%. Negative ROE indicates the company is unprofitable.
What is CASI Pharmaceuticals, Inc.'s free cash flow?
CASI Pharmaceuticals, Inc. (CASI) had negative free cash flow of $29.5M in fiscal year 2024, likely due to heavy capital investments.